Journal article
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
- Abstract:
-
Combined radiochemotherapy is the currently used therapy for locally advanced pancreatic ductal adenocarcinoma (PDAC), but normal tissue toxicity limits its application. Here we test the hypothesis that inhibition of ATR (ATM-Rad3-related) could increase the sensitivity of the cancer cells to radiation or chemotherapy without affecting normal cells. We tested VE-822, an ATR inhibitor, for in vitro and in vivo radiosensitization. Chk1 phosphorylation was used to indicate ATR activity, γH2AX an...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.7MB, Terms of use)
-
- Publisher copy:
- 10.1038/cddis.2012.181
Authors
Funding
Bibliographic Details
- Publisher:
- Nature Publishing Group:
- Journal:
- Cell death and disease More from this journal
- Volume:
- 3
- Issue:
- 12
- Pages:
- e441
- Publication date:
- 2012-01-01
- DOI:
- EISSN:
-
2041-4889
- ISSN:
-
2041-4889
Item Description
- Language:
-
English
- Keywords:
-
- Pubs id:
-
pubs:367719
- UUID:
-
uuid:e3033215-ee1a-4b8f-b91b-1ba8b6ba8250
- Local pid:
-
pubs:367719
- Source identifiers:
-
367719
- Deposit date:
-
2013-11-16
Terms of use
- Copyright holder:
- Macmillan Publishers Limited
- Copyright date:
- 2012
- Notes:
- This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record